Results 21 to 30 of about 255,512 (289)

Potential role of immunotherapy in advanced non-small-cell lung cancer [PDF]

, 2016
Immuno checkpoint inhibitors have ushered in a new era with respect to the treatment of advanced non-small-cell lung cancer. Many patients are not suitable for treatment with epidermal growth factor receptor tyrosine kinase inhibitors (eg, gefitinib ...
Antoniou, Georgios, Catarina, Paulo Esrom, De Mello, Ramon Andrade, Nadine, Sara, Veloso, Ana Flavia   +4 more
core   +3 more sources

Immune Checkpoint Inhibitor-Induced Central Diabetes Insipidus: Looking for the Needle in the Haystack or a Very Rare Side-Effect to Promptly Diagnose?

Frontiers in Oncology, 2022
Immune checkpoint inhibitors have improved the survival in patients affected by an increasing number of malignancies, but they may also trigger various autoimmune side-effects, including endocrinopathies.
Agnese Barnabei, Lidia Strigari, Andrea Corsello, Rosa Maria Paragliola, Luca Falzone, Roberto Salvatori, Salvatore Maria Corsello, Salvatore Maria Corsello, Francesco Torino   +8 more
doaj   +1 more source

The role of immune checkpoint inhibitors in the development and treatment of infectious processes [PDF]

Клиническая практика
The incidence and prevalence of oncological diseases, which are the second most frequent cause of death, is steadily increasing among the population of the Russian Federation.
Dilya A. Mustafina, Aisylu N. Bagautdinova, Milyausha M. Zinatullina, NIkita A. Gorbunov, Elvina T. Zainetdinova, Diana I. Bukharmetova, Daniil Yu. Leonov, Aibike G. Pirmagomedova, Anna E. Chernyshova, Maria P. Markhanos, Anna G. Abgaryan, Arina S. Arustamyan, Konstantin S. Chavro, Farzonakhon Mirzojonova   +13 more
doaj   +1 more source

Development of Extragenital Lichen Sclerosus in Malignant Melanoma Patients Treated With Ipilimumab in Combination With Nivolumab

Frontiers in Oncology, 2020
The immune checkpoint inhibitors opened a new era for the treatment of melanoma. Nowadays, combined immune checkpoint inhibitors are administered to provide additive or synergistic effects on anti-melanoma immunity.
S. Morteza Seyed Jafari, Laurence Feldmeyer, Robert E. Hunger   +2 more
doaj   +1 more source

SnapShot: Immune Checkpoint Inhibitors

Cancer Cell, 2017
Immunotherapy has changed the landscape of cancer treatment. Checkpoint blockade therapies unleash breaks in the immune system and induce long-lasting responses. However, a significant number of patients do not respond (innate resistance), and a subset progress after responding (acquired resistance).
Abril-Rodriguez, Gabriel, Ribas, Antoni
openaire   +4 more sources

Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity

Journal of Experimental & Clinical Cancer Research, 2021
Immune checkpoint inhibitors provide considerable therapeutic benefit in a range of solid cancers as well as in a subgroup of hematological malignancies.
Allan Relecom, Maysaloun Merhi, Varghese Inchakalody, Shahab Uddin, Darawan Rinchai, Davide Bedognetti, Said Dermime   +6 more
doaj   +1 more source

A Role of Therapy that Targets Immune Checkpoint Proteins for the Treatment of Melanoma Brain Metastasis, Liver, Breast, Pancreatic Cancer and Pancreatic Adenocarcinoma

مجله كليه طب الكندي, 2022
Checkpoint inhibitors are a type of immune therapy used to treat different types of cancers. These drugs block different checkpoint proteins, for example, CTLA-4, PD-1, and PD-L1 inhibitors.
Smaa Elsayed Mohammed, Basma Aml Youssef, Doaa Alaa Ghonai, Eman Fares Ahmed, Esraa Gharieb Mohammed, Mai Ashraf Abdo, Mai Essam Mohammed, Rana Gharieb Hassan, Reem Mohammed Mohammed, Rofida Ahmed Abd Al-Azeem, Sarah Adel Swelem, Sarah Ouda Salman, Sarah Mohammed Al-aiyq, Toka Taha Taha, Zainab Khalid Moawad   +14 more
doaj   +1 more source

The Evolving Role of CD8+CD28- Immunosenescent T Cells in Cancer Immunology [PDF]

, 2019
Functional, tumor-specific CD8+ cytotoxic T lymphocytes drive the adaptive immune response to cancer. Thus, induction of their activity is the ultimate aim of all immunotherapies.
Dey, Mahua, Fetcko, Kaleigh, Henriquez, Mario, Huff, Wei X., Kwon, Jae Hyun   +4 more
core   +1 more source

Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives

Frontiers in Pharmacology, 2023
In recent years, cancer immunotherapy has made remarkable achievements. Immune checkpoint inhibitors (ICIs) have been used successfully in several types of cancer in the past decade.
Zherui Liu, Zherui Liu, Yun Zhu, Huan Xie, Zhengsheng Zou, Zhengsheng Zou, Zhengsheng Zou   +6 more
doaj   +1 more source

Predictive biomarkers for checkpoint inhibitor-based immunotherapy: The Galectin-3 signature in NSCLCs [PDF]

, 2019
Checkpoint inhibitor-based immunotherapy is opening a promising scenario in oncology, with objective responses registered in multiple cancer types. However, reliable predictive markers of tumor responsiveness are still lacking.
Bartolazzi A., Capalbo C., Filetti M., Marchetti P., Scafetta G.   +4 more
core   +1 more source